Man Group plc Buys New Shares in Beta Bionics, Inc. $BBNX

Man Group plc purchased a new stake in Beta Bionics, Inc. (NASDAQ:BBNX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 26,770 shares of the company’s stock, valued at approximately $419,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Perceptive Advisors LLC raised its holdings in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares in the last quarter. BlackRock Inc. bought a new position in Beta Bionics in the second quarter valued at approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Beta Bionics during the 4th quarter worth approximately $40,437,000. Bruce & Co. Inc. acquired a new position in shares of Beta Bionics during the 1st quarter worth approximately $5,518,000. Finally, Y Intercept Hong Kong Ltd raised its stake in shares of Beta Bionics by 4,236.8% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock worth $4,868,000 after purchasing an additional 474,651 shares in the last quarter.

Insider Activity at Beta Bionics

In other news, insider Steven Russell sold 4,221 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the transaction, the insider directly owned 169,628 shares of the company’s stock, valued at $3,241,591.08. This represents a 2.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 5,327 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97. Following the sale, the insider owned 124,027 shares of the company’s stock, valued at approximately $2,370,155.97. This represents a 4.12% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 33,262 shares of company stock valued at $604,002. 5.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on BBNX shares. William Blair began coverage on Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group boosted their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Truist Financial upped their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Bank of America cut their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Finally, UBS Group initiated coverage on shares of Beta Bionics in a research report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Beta Bionics Stock Down 2.5%

BBNX opened at $19.42 on Friday. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The business has a 50 day moving average of $17.17 and a 200-day moving average of $13.65. The stock has a market cap of $873.71 million, a price-to-earnings ratio of -11.77 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million for the quarter. As a group, analysts expect that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Beta Bionics Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.